摘要
目的本研究拟观察重组人血小板生成素(rhTPO)对儿童难治性ITP患者的治疗疗效及影响。方法回顾性分析江西省儿童医院自2016年1月到2020年10月间收治入院并同意接受rhTPO治疗的难治性ITP患儿临床资料,按病程分为新发组、持续组和慢性组,分析rhTPO治疗各组难治性ITP的疗效及影响。结果35例患儿中,男性20例,女性15例,其中新诊断的ITP 16例,持续性ITP 9例,慢性ITP 10例。完全反应14/35例(40%),有效17/35例(48.57%),无效4/35例(11.42%),总有效率88.57%(31/35)。不同分组患儿有效率比较差异无统计学意义(P>0.05)。治疗期间,35例患儿均未出现明显临床不良反应。对比使用rhTPO前后血常规相关指标,除血小板计数较前明显增高外,白细胞计数和血小板分布宽度也较前增高,两者有统计学意义(P<0.05)。结论rhTPO有效率高,安全性好,可用于儿童难治性免疫性血小板减少症的治疗。
Objective This study was to observe the therapeutic effect of recombinant human thrombopoietin(rhTPO)on children with refractory ITP.Methods The clinical data of children with refractory ITP who were admitted to Jiangxi Provincial Children's Hospital from January 2016 to October 2020 and agreed to receive rhTPO treatment were retrospectively analyzed.They were divided into new group,persistent group and chronic group according to course of disease,and the efficacy and influence of rhTPO treatment of refractory ITP in each group were analyzed.Results Among the 35 cases,there were 20 males and 15 females,including 16 newly diagnosed ITP,9 persistent ITP and 10 chronic ITP.Complete response was observed in 14/35 cases(40%),effective in 17/35 cases(48.57%),ineffective in 4/35 cases(11.42%),and the total effective rate was 88.57%(31/35).There was no significant difference in the effective rate among different groups(P>0.05).During the treatment period,no obvious clinical adverse reactions occurred in 35 children.Compared with the routine blood indicators before and after the use of rhTPO,in addition to the platelet count was significantly higher than before,the white blood cell count and platelet distribution width were also higher than before,with statistical significance(P<0.05).Conclusion rhTPO is effective and safe,and can be used in the treatment of children refractory immune thrombocytopenia.
作者
吴崇军
徐忠金
熊婷
陈峰
叶瑶
王红
WU Chongjun;XU Zhongjin;XIONG Ting(Department of Hematology,The affiliated Children's Hospital of Nanchang University(Jiangxi Provincial Children's Hospital),Nanchang,Jiangxi,330000)
出处
《江西医药》
CAS
2021年第8期1091-1095,共5页
Jiangxi Medical Journal
基金
江西省卫生计生委科技计划项目,编号20185455
江西省卫生计生委科技计划项目,编号20185443
江西省科技厅应用研究培育计划,编号20181BBG78011。
